Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ONC206 · JZP3507

Small molecule · Antagonist of dopamine receptor D2 (DRD2) and mitochondrial caseinolytic protease P (CLPP) · developed by Jazz Pharmaceuticals

Phase 2 Most advanced trial

JAZZ Developer

2 Registered trials

What is ONC206?

ONC206 is an orally bioavailable small molecule that antagonizes dopamine receptor D2 and acts as an agonist of mitochondrial caseinolytic protease P (ClpP). It inhibits DRD2-mediated signaling and PI3K/Akt and MAPK/ERK pathways, inducing tumor cell apoptosis. It is being studied in advanced pheochromocytoma, paraganglioma, and meningioma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: JZP3507
Drug type: Small molecule
Targets: dopamine receptor D2 (DRD2), mitochondrial caseinolytic protease P (CLPP), protein kinase B (AKT1) (secondary target), extracellular signal-regulated kinase (MAPK1) (secondary target)
Mechanism: Antagonist of dopamine receptor D2 (DRD2) and mitochondrial caseinolytic protease P (CLPP)
Pathways: PI3K/Akt, MAPK/ERK, apoptosis, TRAIL/DR5 signaling
Therapy area: Oncology
Developer: Jazz Pharmaceuticals (JAZZ)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: OW6LM47PNK

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07533942	Phase 2	Meningioma	Recruiting	JAZZ
NCT07282587	Phase 2	Advanced Pheochromocytoma and Paraganglioma	Recruiting	JAZZ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Pheochromocytoma and ParagangliomaMeningiomaPCPG

Other drugs acting on DRD2 / CLPP

Aripiprazole Lauroxil FDA approved Asenapine FDA approved Iloperidone FDA approved Milsaperidone FDA approved

More from Jazz Pharmaceuticals

Asparaginase Erwinia chrysanthemi FDA approved Calcium, Magnesium, Potassium, And Sodium Oxybates FDA approved Daunorubicin And Cytarabine Liposome FDA approved Defibrotide FDA approved Lurbinectedin FDA approved Zanidatamab FDA approved CBD-OS Phase 3 Flezurafenib Phase 1 JZP269 Phase 1 JZP926 Phase 2/3 Nabiximols Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the JAZZ page.

Follow JAZZ, the company behind ONC206

See JAZZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JAZZ catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z